Featured Story

Jake Glanville Talks Hard-Hitting Antibody Discovery

Jake Glanville discusses how therapeutic antibodies can be discovered for use in various therapeutic areas and disease states such as COVID-19

It’s now possible to discover antibodies against even the hardest targets.

Traditionally, the unique biology of GPCRs, ion channels, anti-ids, HIV, and anti-pMHCs makes targeting these with antibodies extremely challenging. Discovering functionally active hits against complex membrane targets, broadly neutralizing antibodies against viruses, and achieving exquisite specificity against major histocompatibility peptide complexes has proven to be difficult, if not impossible, in the past.


Jake Glanville, founder and CEO of Distributed Bio, designed the SuperHuman antibody discovery library and the Tumbler computational antibody optimization technology to discover and optimize thousands of antibodies against even the most difficult targets.

Combining cell selections with next generation sequencing, the platform identifies enriched scFvs against cell surface targets including GPCRs. The resulting diversity of binders optimizes the ability to find functionally active hits. The platform generates picomolar binders, triple-species cross-reactive binders, cell surface receptor-confirmed binders, functionally active antagonists and agonists, and saturated epitope coverage. Jake explains the technology in clear and concise terms in the following webinar.

Jake also explains the Tumbler antibody optimization technology, which generates variants of a starting clone​ and optimizes affinity, thermostability, expression, and immunogenicity – delivering the best possible lead candidates. Tune in to understand this remarkable platform and learn what it could mean for your discovery program.

Together, Charles River and Distributed Bio offer an end-to-end solution for therapeutic antibody discovery and development that enables efficient movement from discovery to approval including lead isolation, lead optimization, lead characterization, preclinical development, and clinical development.